Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML. - Short NJ; Kantarjian HM; Daver NG; Azevedo RS; Karrar O; DiNardo CD; Kadia TM; Yilmaz M; Maroun MM; Hachem MCR; Borthakur G; Issa GC; et al. (Blood advances, 2026)